|

BMS-986504 Clinical Trials

6 actively recruiting trials across 2 locations

Also known as: MRTX1719

Pipeline

Early 1: 1Phase 1: 2Phase 2: 1Phase 2/3: 2

Top Sponsors

  • Bristol-Myers Squibb5
  • Nader Sanai1

Indications

  • Cancer6
  • Lung Cancer2
  • Glioblastoma WHO Grade IV1
  • Advanced Solid Tumors With Homozygous MTAP Deletion1
  • Metastatic Non-small Cell Lung Cancer With MTAP Deletion1

Other2 trials

A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
Phase 1
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
Phase 1

Anchorage, Alaska2 trials

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Alaska Oncology and Hematology

Phase 2
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Alaska Oncology and Hematology

Phase 2/3

Phoenix, Arizona2 trials

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Local Institution - 0142

Phase 2/3
Clinical Trial of BMS-986504 in Recurrent GBM Patients

St. Joseph's Hospital and Medical Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.